Evidence map›Paper›PMID 28035618›Full record

ArticleInternational urology and nephrology2017

WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach.

Wolfgang Otto, Johannes Breyer, Sonja Herdegen, Fabian Eder, Simone Bertz, Matthias May, Roman Mayr, Eva M Lausenmeyer, Stefan Denzinger, Bas W G van Rhijn and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in International urology and nephrology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. EMT and cancer: what clinicians should know.Nature reviews. Clinical oncology · 2025
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. The role of cell adhesion molecules in the progression of bladder urothelial carcinomas.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Wolfgang OttoDepartment of Urology, University of Regensburg, Landshuterstr. 65, 93053, Regensburg, Germany.
Johannes BreyerDepartment of Urology, University of Regensburg, Landshuterstr. 65, 93053, Regensburg, Germany. Johannes.breyer@ukr.de.ORCID http://orcid.org/0000-0003-0674-4150
Sonja HerdegenDepartment of Urology, University of Regensburg, Landshuterstr. 65, 93053, Regensburg, Germany.
Fabian EderInstitute of Pathology, University of Regensburg, Regensburg, Germany.
Simone BertzInstitute of Pathology, University of Erlangen-Nuremberg, Erlangen, Germany.
Matthias MayDepartment of Urology, Hospital St. Elisabeth, Straubing, Germany.
Roman MayrDepartment of Urology, University of Regensburg, Landshuterstr. 65, 93053, Regensburg, Germany.
Eva M LausenmeyerDepartment of Urology, University of Regensburg, Landshuterstr. 65, 93053, Regensburg, Germany.
Stefan DenzingerDepartment of Urology, University of Regensburg, Landshuterstr. 65, 93053, Regensburg, Germany.
Bas W G van RhijnDepartment of Urology, University of Regensburg, Landshuterstr. 65, 93053, Regensburg, Germany.
Maximilian BurgerDepartment of Urology, University of Regensburg, Landshuterstr. 65, 93053, Regensburg, Germany.
Arndt HartmannInstitute of Pathology, University of Erlangen-Nuremberg, Erlangen, Germany.
University of Regensburg · DEFriedrich-Alexander-Universität Erlangen-Nürnberg · DEBarmherzige Brüder Klinikum St. Elisabeth in Straubing · DEThe Netherlands Cancer Institute · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeStage pT1 urothelial bladder cancer (UBC) is characterized as a challenging subentity of urothelial carcinoma with an unforeseeable clinical course. In addition to more or less established clinical and histopathological features, we evaluated the role of epithelial-mesenchymal transition (EMT) marker E-cadherin, shown to be of prognostic value in muscle-invasive disease, regarding the prognosis of stage pT1 high-grade (hg) UBC.

methodsTissue of 226 stage pT1 hg UBC patients from transurethral resection could be immunostained for E-cadherin. Kaplan-Meier analysis and univariate and multivariate Cox regression analyses regarding progression-free (PFS) and cancer-specific survival (CSS) were performed.

resultsAberrant expression of E-cadherin was recognized in 74% of patients. Kaplan-Meier analysis showed that aberrant E-cadherin expression was associated with worse 10-year PFS (62 vs. 90%, p = 0.045). In univariate analysis, aberrant E-cadherin staining, associated carcinoma in situ, grading 3 after WHO classification 1973 and infiltrative growth pattern at the invasion front were the statistically significant predictive factors for worse PFS, only infiltrative growth pattern for CSS. With regard to progression, grading 3 after WHO classification of 1973 (HR 6.49; CI 1.54-27.28, p = 0.011) and infiltrative tumor invasion pattern (HR 2.06; CI 1.10-3.86, p = 0.024) revealed as independent factors for PFS, and there was a trend also for E-cadherin expression (HR 0.45; CI 0.19-1.06; p = 0.068). Regarding CSS, infiltrative tumor growth pattern (HR 3.79; CI 1.67-8.60, p = 0.001) was the only statistically significantly independent predictive factor in multivariate Cox regression analysis.

conclusionsBeside invasion growth pattern and WHO grading 1973 that achieved to be independent prognostic factors, there was a trend for the parameter E-cadherin expression to be of predictive value for PFS in stage pT1 hg urothelial bladder carcinoma after organ-sparing approach. Further studies on genetic level are warranted to define the distinct role of EMT in early-invasive UBC.

Indexed as

AgedBiomarkers, TumorCadherinsCarcinoma in SituCarcinoma, Transitional CellDisease-Free SurvivalDisease ProgressionFemaleHumansMaleNeoplasm GradingNeoplasm InvasivenessNeoplasm StagingOrgan Sparing TreatmentsPredictive Value of TestsSurvival RateBiomarkers, TumorCadherinsE-cadherinEpithelial–mesenchymal transitionImmunohistochemistryStage pT1 bladder cancerWHO grading classifications

Identifiers

PMID28035618
OpenAlexW2564762844

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.